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A B S T R A C T
New procedures for phthalate mixture risk assessments (MRAs) focused on male developmental toxicity (anti-
androgenicity) are overdue. Previous efforts suffer from several shortcomings: There is a lack of consistency in
terms of the phthalates entered into the assessments, and in the choice of tolerable intakes. Many of these values
do not reflect new evidence about low dose male developmental effects. Nearly all previous mixture risk as-
sessments have focused solely on phthalates, with no regard for exposures to other chemicals that also induce
male developmental toxicity, leading to underestimations of risks. Here, we address these weaknesses and in-
consistencies by proposing criteria for the selection of phthalates for MRA based on structure-activity re-
lationships. We suggest new reference doses for phthalates for use in MRA, as follows: DBP 6.7 μg/kg/d, DIBP
100 μg/kg/d, BBP 10 μg/kg/d, DEHP 10 μg/kg/d, DINP 59 μg/kg/d. We conclude that the fixation on the Hazard
Index (HI) = 1 as signalling acceptable combined phthalate exposures is misguided as it ignores co-exposure to
other anti-androgenic chemicals that also contribute to male developmental risks. Until more comprehensive
assessments of phthalates in combination with other anti-androgens become feasible, we propose the use of a HI
of 0.1–0.2 as a benchmark for interpreting phthalate mixture risk assessments.
1. Introduction
Phthalates (for abbreviations, trivial names and side chain lengths
see Table 1) are priority pollutants widely used as additives and plas-
ticisers in a multitude of consumer articles such as plastic bags, poly-
vinyl flooring and personal care products. They also occur in pharma-
ceuticals, medical devices, cleaning materials and children's toys. Due
to their high production volume and extensive use, multiple phthalates
have entered the indoor environment and the food chain, with wide-
spread human exposure.
Exposure to some of the phthalates is a concern as these substances
are developmental and reproductive toxicants. Studies with laboratory
rodents exposed during gestation have shown that phthalates with a
certain side chain length induce agenesis of testis and epididymis, to-
gether with often complete agenesis of the gubernacular cords and poor
semen quality (Gray et al., 2004). This effect spectrum (“phthalate
syndrome”, also referred to as “anti-androgenicity”) derives from the
ability of phthalates to suppress InsL3 peptide hormone production and
testosterone synthesis in foetal Leydig cells. Without InsL3, the gu-
bernacular cord cannot develop properly, leading to the disruption of
testis descent. Phthalates also down-regulate genes involved in the
transport of cholesterol, a precursor required for androgen synthesis.
The resulting diminished testosterone levels in foetal Leydig cells alter
their developmental trajectory such that they continue to proliferate
but fail to differentiate properly. Consequently, Leydig cells in phtha-
late exposed foetal testes typically appear in large clusters. The sup-
pressed testicular testosterone levels also result in reduced sperm
numbers and have knock-on effects on dihydrotestosterone (DHT)
concentrations. Reduced DHT action leads to shortened (feminised)
anogenital distance (AGD) and retained nipples in male rats exposed to
phthalates in foetal life (Schwartz et al. 2019). Feminised AGDs have
also been associated with phthalate exposures in humans (Dorman
et al., 2018) and there are associations with reduced InsL3 levels
(Chang et al., 2017). As is common with many endocrine disruptors,
phthalates affect multiple endpoints that exist as a constellation and
constitute a syndrome.
Several experimental studies have shown that multiple phthalates
act together to produce adverse reproductive and developmental effects
(reviewed in Howdeshell et al. 2017; Kortenkamp, 2019). The combi-
nations usually show stronger effects than any single phthalate in the
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mixture on its own. In the light of such observations, the US National
Academy of Sciences has called for mixture risk assessments of phtha-
lates and suggested the use of the Hazard Index (HI) approach (USNAS,
2008).
1.1. Previous phthalate mixture risk assessments
The HI is a simple screening tool in mixture risk assessments (MRA)
based on summing up risk quotients (RQ) of exposures and so-called
reference doses (RfD) for relevant health endpoints. The utility of the HI
approach for combined phthalate exposures was first shown by Benson
(2009) and then expanded by Kortenkamp and Faust (2010) to include
exposures to other substances capable of producing reproductive and
developmental toxicity by endocrine modes of action. Since then, many
phthalate MRAs have been published. They all focused on effects re-
lated to gestational exposure and the phthalate syndrome and have, to
varying degrees, revealed concerns about combined phthalate ex-
posures. However, there are several problems with these efforts:
First, comparisons of evaluation outcomes across studies are com-




AIC Akaike Information Criterion
BBP Benzyl butyl phthalate
BMD Benchmark dose







ECHA European Chemicals Agency
ECETOC European Centre for Ecotoxicology and Toxicology of
Chemicals
EFSA European Food Safety Authority
EPA Environmental Protection Agency
HI Hazard Index
LOAEL Lowest observed adverse effect level
MCR Maximal cumulative ratio
MoE Margin of exposure
MRA Mixture risk assessment
NOAEL No observed adverse effect level
OECD Organisation for Economic Cooperation and Development
POD Point of Departure
PODI Point of Departure Index
RQ Risk quotient
RfD Reference dose
TDI Tolerable daily intake
UF Uncertainty factor
US EPA US Environmental Protection Agency
USNAS US National Academy of Sciences
Table 1
Phthalates and their common names.
Grey: Phthalates active in inducing the phthalate syndrome, a form of male developmental disorders.
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into the assessments (Table 2). Some studies considered only 2 or 3
phthalates, most included DBP, DIBP, BBP, and DEHP, while some left
out DINP. Yet others entered DEP and DIDP. Recent investigations of
structure-activity relationships (Li et al., 2019) might provide sys-
tematic criteria for the choice of phthalates to be considered in MRAs.
Second, similar inconsistencies concern the choice of RfD for the
single phthalates. Most studies based their assessment on the tolerable
daily intakes (TDI) published by EFSA or the RfD AA for developmental
toxicity through endocrine modes of action proposed by Kortenkamp
and Faust (2010). Christensen and colleagues (Christensen et al. 2014)
also considered the TDIs proposed by the Danish EPA (2009) and in-
troduced a revised value for DEHP. As there is no EFSA TDI for DIBP,
most authors filled this gap by adopting the EFSA TDI for the straight
chain analogue DBP (EFSA, 2005a). However, since 2010, new data
about DIBP have become available which could be used to arrive at
more accurate assessments (Yost et al., 2019). Furthermore, the EFSA
TDIs for DINP and DIDP that were used in phthalate MRAs are based on
effects unrelated to reproductive and developmental toxicity, such as
hepatic or renal effects. This compromises the comparability and con-
sistency of the risk quotients that are summed up when using the HI
approach. The RfD for DINP requires an update in the light of evidence
of low dose effects that has emerged since 2010 and the same applies to
DEHP. Thus, it is timely to review the RfDs for phthalates and to derive
new and harmonised values.
Third, as argued by Wilkinson and colleagues (Wilkinson et al.,
2000), the outcome of MRAs using the HI approach may be biased
through the use of RfDs that were derived by application of differing
uncertainty factors (UF). As shown in Table 3, UFs between 100 and
1000 were commonly used to establish phthalate RfDs. The overall UFs
are the composite of two different kinds of sub-factors: Those for the
adjustment of differences in the data quality of experimental values
(e.g. LOAEL to NOAEL extrapolations) and those necessary for the
realisation of protection goals enshrined in various chemical legisla-
tions (e.g. animal to human extrapolation, increased protection against
carcinogens). The mixing of these different UFs may then yield RfDs
that are a poor reflection of the potency of the various phthalates. The
resulting distorting effect may not be so much on the quantitative
outcome of the HI MRA, but rather on the rank order of the single risk
quotients (RQ). This may lead to misguided decisions in terms of the
phthalates to be prioritised for risk reduction measures in risk man-
agement. However, in mixture toxicology, data that strictly reflect the
toxic potency of mixture components must be used for the evaluation of
experimentally observed combined effects. Although the problem does
not arise when using the HI with RfDs based on the same UFs, it may be
more appropriate to use mixture risk assessment methods that imple-
ment strict separations of the subclasses of UFs. One such method is the
Point-of Departure-Index (PODI) which sums up RQs derived from
Points of Departure (NOAELs, benchmark doses).
Last, except for Kortenkamp and Faust (2010), all studies have fo-
cused solely on phthalates, without taking account of other chemicals
capable of disrupting male sexual development through hormonal
modes of action. The unspoken assumption behind this stance is the
belief that only chemicals with a common mechanism of action qualify
for inclusion in MRA. Without much further consideration, the practical
implementation of this commonality criterion (which is mandated in
certain legalities for certain chemicals, such as for pesticides in the US
Food Quality Protection Act) then reduces to simply grouping chemicals
with similar structural features, such as phthalates. However, this
Table 2
Overview of phthalate mixture risk assessments.
Author Country/region Phthalates considered for HI Number of
phthalates
Population TDI source HI 95th percentile
Bekö et al. (2013) Denmark DBP; DIBP; DEHP 3 Children EFSA 2.3
Chang et al., 2017 Taiwan DBP; DIBP; BBP; DEHP 4 General population EFSA, DIBP as DBP >1
Chen et al., 2019 China DBP; DEHP 2 Pregnant women
(primiparas)
EFSA 3
Christensen et al., 2014 USA DBP, BBP, DEHP, DINP 4 General population EFSA 0.87
Christensen et al., 2014 USA DBP; DIBP; BBP; DEHP; DINP 5 General population DanEPA 0.96
Dewalque et al., 2014 Belgium DBP; DIBP; BBP; DEHP 4 Adults EFSA, DIBP as DBP 1.22
Dewalque et al., 2015 Belgium DBP; DIBP; BBP; DEHP 4 Adults Kortenkamp & Faust 0.31
Dong et al., 2018 China DBP; DIBP; BBP; DEHP 4 Women 20–44 y Kortenkamp & Faust 0.24
Dong et al., 2018 China DBP; DIBP; BBP; DEHP 4 Women 20–44 y EFSA, DIBP as DBP 0.46
Frederiksen et al., 2014 Denmark DBP; DIBP; BBP; DEHP 4 Infants < 14 months EFSA, DIBP as DBP >1
Gao et al., 2016 China DBP; DIBP; DEHP 3 Young adults EFSA, DIBP as DBP >1
Gao et al., 2016 China DBP; DIBP; DEHP 3 Young adults Kortenkamp & Faust > 1
Gao et al., 2017 China DEP; DBP; BBP; DEHP 4 Mother-neonate pairs EFSA 1.85
Garí et al., 2019 Poland DBP; DIBP; BBP; DEHP 4 Children 7 y Kortenkamp & Faust without DINP ~1
Hartmann et al., 2015 Austria DBP; DIBP; BBP; DEHP 4 Children, adults, seniors EFSA, DIBP as DBP 0.15–2.7
Hartmann et al., 2015 Austria DBP; DIBP; BBP; DEHP 4 Children, adults, seniors Kortenkamp & Faust 0.05–0.69
Jeddi et al., 2018 Iran DBP; BBP; DEHP 3 Children and adolescents EFSA 0.44–0.65
Jeddi et al., 2018 Iran DBP; BBP; DEHP 3 Children and adolescents Kortenkamp & Faust 0.4–0.6
Kim et al., 2017 South Korea DBP; DIBP; DEHP; DEP 4 Infants < 15 months lowest value of Kortenkamp &
Faust and EFSA
>1
Hyun Kim, 2018 South Korea DBP; DEHP 2 Children, adolescents EFSA >1
Kranich et al., 2014 Denmark DBP; BBP; DEHP; DINP 4 Men EFSA 0.5–0.88
Kranich et al., 2014 Denmark DBP; DIBP; BBP; DEHP; DINP 5 Men Kortenkamp & Faust 0.32–1.19
Lioy et al., 2015 USA DBP; DIBP; BBP; DEHP; DINP 5 Pregnant women Kortenkamp & Faust; DIBP as DBP 6.1
Lioy et al., 2015 USA DBP; DIBP; BBP; DEHP; DINP 5 Infants Kortenkamp & Faust; DIBP as DBP 0.96
Reyes and Price
(2018a)
USA DBP; DIBP; BBP; DEHP;
DINP: DIDP
6 General population EFSA; Saillenfait; CPSC >1
Reyes and Price
(2018b)
USA DBP; DIBP; BBP; DEHP;
DINP: DIDP
6 General population EFSA; Saillenfait; CPSC >1
Rocha et al., 2017 Brazil DBP; DIBP; DEHP 3 Children 6–14 y EFSA, DIBP as DBP 3.4
Rocha et al., 2017 Brazil DBP; DIBP; DEHP 3 Children 6–14 y Kortenkamp & Faust 2.1
Soborg et al., 2012 Denmark DBP; DIBP; BBP; DEHP 4 Children, adolescents EFSA, DIBP as DBP 1.3
Soborg et al., 2012 Denmark DBP; DIBP; BBP; DEHP; DINP 5 Children, adolescents Kortenkamp & Faust 0.43
Wang et al., 2015 China DBP; DIBP; BBP; DEHP 4 Children 8–11 y EFSA, DIBP as DBP 3.05
Zhang et al., 2019 China DBP; DIBP; DEHP 3 All ages, e-recycling sites EFSA, DIBP as DBP >1
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Table 3
Tolerable daily intakes and reference doses used in previous phthalate mixture risk assessments.
EFSA 2005a,b,c,d
POD (mg/kg/d) UF TDI (μg/kg/d)
DBP 2 (LOAEL) 200 10
Endpoint Germ cell development
Species Rat
Reference Lee et al. (2004)
DIBP no value no value
BBP 50 (NOAEL) 100 500
Endpoint AGD reduction
Species Rat
Reference Tyl et al. (2004)
DEHP 5 (NOAEL) 100 50
Endpoint Testicular toxicity
Species Rat
Reference Wolfe and Layton 2003
DINP 15 (NOAEL) 100 150
Endpoint Hepatic and renal effects
Species Rat




POD (mg/kg/d) UF TDI (μg/kg/d)
DBP 2 (LOAEL) 2.5 interspecies 6.7
Endpoint Germ cell development 4 allometric
Species Rat 10 intraspecies
Reference Lee et al. (2004) 3 LOAEL - NOAEL
300 overall
DIBP 125 (NOAEL) 2.5 interspecies 1250
Endpoint Retained nipples, AGD 4 allometric
Species Rat 10 intraspecies
Reference Saillenfait et al. (2008) 100 overall
BBP 50 (NOAEL) 2.5 interspecies 500
Endpoint AGD 4 allometric
Species Rat 10 intraspecies
Reference Tyl et al. (2004) 100 overall
DEHP 5 (NOAEL) 2.5 interspecies 50
Endpoint Reduced testic weight 4 allometric
Species Rat 10 intraspecies
Reference Wolfe and Layton 2003 100 overall
DINP 276 (NOAEL) 2.5 interspecies 1600
Endpoint Reduced testic weight 7 allometric
Species Mouse 10 intraspecies
Kortenkamp and Faust (2010)
POD (mg/kg/d) UF TDI (μg/kg/d)








BBP 66 (BMDL) 200 330
Endpoint T suppression
Species Rat
(continued on next page)
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largely ignores the recommendations of USNAS (2008) which called for
including other endocrine disruptors in phthalates MRAs. There is
ample evidence that chemicals capable of inducing male developmental
toxicity through a multitude of mechanisms can act together with
phthalates to produce adverse effects (Howdeshell et al., 2017; Conley
et al., 2018; Kortenkamp, 2019). This includes chemicals as diverse as
anti-androgenic pesticides (vinclozolin, prochloraz, procymidone, li-
nuron), pain killers (paracetamol, aspirin, ibuprofen), other pharma-
ceuticals (finasteride, ketoconazole, the lipid-lowering drug simvastin),
poly-chlorinated dibenzo-dioxins and other dioxin-like pollutants and
phenolics (bisphenol A, butylparaben) (Kortenkamp, 2019). Con-
sideration of co-exposures to such substances is critical when it comes
to interpreting exceedances of cumulative acceptable exposures to
phthalates. In all phthalate MRAs published thus far, an HI of up to 1
was judged acceptable. However, this leaves no room for co-exposures
to any of the above chemicals. Thus, new criteria are required for the
quantitative evaluation of the outcome of phthalate MRAs.
To put the derivation of new phthalate reference doses for MRA on a
sound footing, we will first consider data requirements for MRA from
the viewpoint of the scientific principles of experimental mixture effects
assessments. This will clarify the data needs that should ideally be met
for MRA and will provide valuable orientations for the procedures and
approaches we propose.
1.2. Data requirements for mixture risk assessments and the simplifying
assumptions of the HI and PODI approaches
In experimental assessments of mixture effects (Howdeshell et al.,
2008a,b; Christiansen et al., 2009), the expected combined toxicity is
calculated based on information about the toxicity of all mixture
components and their prevalence in the mixture. With the aim of es-
tablishing common effect doses, the effects of all components are de-
termined for the same measurement endpoint and effect magnitude, in
the same test under identical experimental conditions, usually by dose-
response analysis.
These data requirements cannot be met in MRAs conducted in
regulatory practice. Instead, MRAs usually have to rely on data from
different experimental studies and with differing measurement end-
points. To overcome this problem and to make MRA viable with readily
available data, the HI (Teuschler and Hertzberg, 1995) and PODI
(Wilkinson et al., 2000) were introduced as pragmatic simplifications of
the dose addition concept. These simplifications concern the following
aspects:
Dose addition relies on RQs derived from doses that correspond to
the same effect magnitude (effect doses such as ED10 etc.). However,
the RfDs that are used as input values to obtain the RQs in the HI do not
always correspond to a uniform effect dose. As already discussed, UFs of
differing magnitudes may have a distorting influence. In addition, the
NOAELs and LOAELs that are needed to derive a RfD are not tox-
icological metrics associated with the same effect magnitude. Instead,
these values are single point estimates that do not incorporate dose-
response data and are artefacts of experimental design (dose selection,
dose spacing). They may correspond to varying effect magnitudes of up
to 30% (Moore and Caux, 1997).
To blur matters further, the NOAELs and LOAELs used to derive
RfDs for phthalates may refer to different toxicity endpoints determined
in different test species. For example, because the EFSA TDIs for DIDP
and DINP were based on hepatic toxicity (for DIDP in the dog, DINP in
the rat), any HI based on these EFSA values together with those for
other phthalates mixes estimates of developmental and reproductive
toxicity with those of hepatic toxicity measured in different species.
While this is an extreme case, the phthalate RfDs derived for male de-
velopmental toxicity (the phthalate syndrome) also do not always
correspond to the same measurement endpoints. Some rely on sup-
pression of testosterone synthesis, others e.g. on AGD changes. To a
certain degree, this cannot be avoided and is due to the multiple end-
points affected by phthalates which materialise as a syndrome.
Thus, the HI introduces four sources of uncertainty that impact on
Table 3 (continued)
Reference USNAS (2008)
DEHP 3 (NOAEL) 100 30
Endpoint Nipple retention
Species Rat
Reference Christiansen et al. (2009)
DINP 750 (LOAEL) 500 1500
Endpoint T suppression
Species Rat
Reference Gray et al. 2000; Borch et al. 2004
Christensen et al. (2014)
POD (mg/kg/d) UF TDI (μg/kg/d)
DEHP 3 (LOAEL) 10 LOAEL to NOAEL 3
Endpoint Mild dysgenesis of genitalia 100 interspecies
Species Rat
Reference Christiansen et al. (2010) 1000 overall
References.
Lee et al. (2004) Toxicology 2003: 221.
Tyl et al. (2004) Reproductive Toxicology 18:241.
Wolfe and Layton (2003) Technical Report.
Saillenfait et al. (2008) Reproductive Toxicology 26:107.
Aristech et al. (1995) in: European Chemicals Bureau (2003). European Union Risk Assessment Report. 1,2-benzenedicarboxylic acid, di-C8-10- branched alkyl esters,
C9-rich and di-“isononyl” phthalate (DINP) Vol. 35.
2nd. priority list. http://ecb.jrc.ec.europa.eu/DOCUMENTS/Existing-Chemicals/RISK_ASSESSMENT/REPORT/dinpreport046.pdf.
USNAS (2008) Phthalates and cumulative risk assessment: The tasks ahead, National Academy Press, Washington DC.
Gray et al. (2000) Toxicological Sciences 58:350.
Borch et al. (2004) Reproductive Toxicology 18:53.
Christiansen et al. (2010) Reproductive Toxicology 30:313.
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the accuracy of assessments of mixture risks: it mixes different UFs,
inexactly defined effect sizes, different toxicity endpoints and different
species. While it will be impossible to reach the consistency of the data
that form the input for evaluating experimental mixture studies, efforts
should be made to choose input values that approximate these stan-
dards as much as possible. For phthalate MRAs, this could be achieved
in the following ways:
First, to mitigate the potential distorting influence of different UFs,
Wilkinson et al. (2000) suggested that UFs needed to even out differ-
ences in data quality should be distinguished from those required to
realise protection goals. For example, UFs of 3–10 are applied to ex-
trapolate from LOAELs to NOAELs (ECHA, 2012). Such adjustments are
necessary to obtain toxicological metrics that better reflect potency
differences between phthalates. By allowing the summing up of RQs
proportional to the potency of the chemicals in the mixture, they
achieve better alignment with the scientific principles of dose addition.
In contrast, UFs applied for realising protection goals go far beyond
matters related to potency. They are used to deal with numerous other
issues, including animal to human extrapolations and protection from
severe and irreversible toxicity such as carcinogenicity for which very
large UFs (1000) can be applied. In principle, the HI is ill-suited to
achieve the necessary separation of potency-adjustment issues from
policy-driven considerations, as it aggregates the different UFs at the
level of the RQ for a single mixture component. In this respect, the PODI
is better equipped to accomplish the required approximation to the
principles of dose addition. By summing up RQs based on points of
departure, it employs toxicological metrics more closely related to po-
tency differences. The realisation of protection goals is achieved by
applying an UF to the sum of RQs, the PODI, i.e. at the level of ag-
gregation of mixture effects, and not at the level of a single mixture
component. In this way, more transparency can be realised by de-
taching UFs employed for purposes of data adjustment from those
dealing with other extrapolation issues. If, however, the UFs for all
components are of the same magnitude, these distinctions are irrele-
vant. Under such conditions both HI and PODI will yield similar results.
As shown in Table 3, UFs ranging from 100 to 1000 have been applied
in the case of phthalates, and it remains to be assessed whether this has
a distorting effect on HI calculations.
Second, to deal with the distorting influence of inexactly defined
effect sizes associated with NOAELs and LOAELs, it is desirable to rely
on benchmark doses as much as possible, if information suitable for the
estimation of benchmark doses is available. For the RfDs proposed by
Kortenkamp and Faust (2010) this could only be realised for DBP, DIBP
and BBP. We recognise that it may be difficult to achieve this goal, due
to limitations in data quality, especially with quantal response data
(e.g. number of animals affected by spermatocyte dysgenesis).
Third, the ideal solution to the problem of mixing different toxicity
endpoints during the summing up of RQ would be to select an outcome
common to all phthalates. The suppression of foetal testicular testos-
terone levels seen after gestational exposure to phthalates would be a
suitable candidate. However, exclusive reliance on this endpoint may
lead to unsatisfactory situations. Some phthalates produce effects as-
sociated with the phthalate syndrome at lower doses than those asso-
ciated with suppressions of testosterone synthesis. An example is DEHP:
The lower one-sided 95% confidence interval of the benchmark dose
associated with testicular testosterone suppression is 31 mg/kg/d
(USNAS, 2008), calculated from the data by Howdeshell et al.
(2008a,b). However, the NOAEL for retained nipples is 3 mg/kg/d
(Christiansen et al., 2009), ten-fold lower. Even at the NOAEL of 3 mg/
kg/d there was mild dysgenesis of the genitalia in gestationally exposed
male rats, which means that this dose must be designated a LOAEL and
not a NOAEL (Christiansen et al., 2010). This example shows that it is
necessary to strike a balance between achieving consistency in the in-
terest of approximating the scientific principles of dose addition and
being protective by choosing the most sensitive endpoint. When es-
tablishing RfDs for use in MRA it is suggested to resolve this issue by
selecting toxicity measurement endpoints related to elements of the
phthalate syndrome. For each phthalate, the most sensitive phthalate
syndrome endpoint should be used. This will exclude the use of RfDs
based on toxicity endpoints related to general toxicity, such as hepatic
or renal toxicity. The EFSA TDIs for DINP and DIDP are therefore un-
suitable for phthalate MRA with a focus on male developmental toxi-
city. In general, it should be emphasised that RfDs derived for use in
MRA are not suited for general, single compound-based risk assess-
ments. To make this distinction, we will designate them as RfD AA
(AA = anti-androgenicity), as previously in Kortenkamp and Faust
(2010).
1.3. Structure of this paper
In this paper, we review the TDIs for phthalates used in previous
MRAs and establish new revised RfD's and corresponding Points of
Departure (POD) for male developmental toxicity through anti-andro-
genic modes of action (the phthalate syndrome). We apply the revised
RfD's to phthalate intake estimates used in previous MRAs and compare
the outcome with earlier evaluations. This is followed by a comparison
between the HI approach and the PODI. Finally, we develop criteria
that may help to better judge the point when acceptable combined
exposures to phthalates are exceeded by taking account of potential co-
exposures to other developmental toxicants.
2. Materials and methods
2.1. Data collection
To capture previous phthalate MRAs, we undertook literature
searches in pubmed and Web of Science using the search string <
phthalate* AND Hazard Index> . The search was conducted in May
2019 and returned 57 records. Studies estimating phthalate exposures
by measuring urinary levels of phthalate metabolites qualified for in-
clusion. We excluded assessments that focused on exposures from spe-
cific products such as baby cosmetics. Elimination of duplicates resulted
in a list of 23 studies (Bekö et al., 2013), (Chang et al., 2017), (Chen
et al., 2019), (Christensen et al., 2014), (Dewalque et al., 2014),
(Dewalque et al., 2015), (Dong et al., 2018), (Frederiksen et al., 2014),
(Gao et al., 2017), (Gao et al., 2016), (Garí et al., 2019), (Hartmann
et al., 2015), (Jeddi et al., 2018), (Kim et al., 2017), (Hyun Kim, 2018),
(Kranich et al., 2014), (Lioy et al., 2015), (Reyes and Price, 2018b),
(Reyes and Price, 2018a), (Rocha et al., 2017), (Søborg et al., 2012),
(Wang et al., 2015), (Zhang et al., 2019) (Table 2).
To identify studies that appeared after 2010 which describe effects
related to the phthalate syndrome below the doses of studies used to
establish the TDIs by EFSA (EFSA, 2005b) (EFSA, 2005c) (EFSA, 2005d)
(EFSA, 2005d), the Danish EPA (2009) or Kortenkamp and Faust (2010)
(Table 3), we relied on the systematic reviews by Dorman et al. (2018)
and Yost et al. (2019). In addition, we conducted literature searches
(Web of Science and pubmed) using the search string “(DINP OR DiNP
OR diisononylphthal*) AND development*”. Equivalent searches were
conducted for DBP, DIBP, BBP and DEHP. The records were manually
searched for relevance and only studies describing developmental
toxicity relevant to the phthalate syndrome at doses lower than those
used to derive existing reference doses in the rat or the mouse were
included.
2.2. Benchmark dose estimations and derivation of reference doses
We conducted benchmark dose modelling using a benchmark re-
sponse of 5% for suppression of testosterone synthesis, a continuous
response endpoint. For quantal endpoints, relevant to DBP and DEHP
(reduced spermatocyte development and testicular dysgenesis, respec-
tively) we applied a benchmark response of 10%. However, due to
limitations in data quality of the relevant studies (Lee et al. 2004;
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Christiansen et al. 2010) this returned benchmark doses (lower bounds)
of 0. For the calculation of the benchmark dose confidence intervals for
DIBP, BBP and DINP we employed model averaging, as recommended
in EFSA guidance (EFSA et al., 2017), and used the lower bound
benchmark dose (BMDL) as point of departure (PROAST tool version
66.39 (EFSA et al., 2017)).
To derive Reference Doses for anti-androgenicity (RfD AA) the
BMDL were combined with an UF = 100. The outcome of the BMDL
estimations is reported in Supplementary Information.
3. Results
3.1. Phthalates to be included in mixture risk assessments
Not all phthalates can induce the phthalate syndrome, and among
those that show effects, there are marked potency differences.
According to the extensive investigations of structure-activity re-
lationships conducted by Li et al. (2019) and Furr et al. (2014), potency
depends on the ester side chain length and the degree of branching of
the side chain. Phthalates with too short (C1 – C3) or too long (> C8)
linear side chains are of very low potency, while side chain lengths of
between C4 and C7 confer strong activity. With branched side chains, a
length of between C4 and C9 is associated with male developmental
toxicity. Based on these insights, phthalates with linear side chains of
C1–C3 and>C8 can be excluded from the MRA. The same applies to
branched side chains with C1–C3 and>C10. Thus, the phthalates to be
subjected to a MRA should comprise (arranged according to alkyl chain
length): DIBP, DBP, DiPP, DPP, DNHP, DCHP, BBP, DIHP, DHP, DEHP
and DINP (Table 1). To accommodate future shifts in usage patterns
that might arise from phthalate substitutions, this selection is based
entirely on criteria of hazard assessment and does not consider usage or
human exposure. This list might not be exhausting and might include
additional phthalates with mixed alkyl chain lengths such as Di-C7-11-
(linear and branched)-alkyl phthalate (DHNUP) which contains several
relevant structural motifs.
3.2. Revised and updated PODs and RfDs AA for use in MRA
Previous phthalate MRAs have employed mainly two sets of RfDs,
the TDIs derived by EFSA (2005a, b, c, d) and the RfD AA suggested by
Kortenkamp and Faust (2010) (Table 3). Some studies also used USEPA
RfDs, but as these values are based on toxicity endpoints not relevant to
the phthalate syndrome they are not considered here. Christensen et al.
(2014) are the only authors who also relied on the anti-androgenicity
TDIs derived by the Danish EPA (2009). As shown in Table 3, these sets
of values vary to a certain degree.
Our goal is to propose a new set of values, derived by following
clear and consistent decision rules that accommodate the requirements
for MRAs, as outlined in the Introduction. We suggest achieving con-
sistency by relying as much as possible on a common endpoint relevant
to the phthalate syndrome measured in the rat. For most phthalates this
will be suppression of testosterone synthesis in the foetal testis, a key
event for the manifestation of the phthalate syndrome. If there is evi-
dence of other, more sensitive effects related to the syndrome that occur
at lower doses, the corresponding PODs will be chosen as the basis for
RfDs.
The question of adversity deserves consideration. As discussed, anti-
androgenicity in terms of the phthalate syndrome materialises as a
constellation of effects, including poor semen quality, incomplete de-
velopment of spermatocytes, abnormal clusters of Leydig cells, multi-
nucleated gonocytes, suppression of testosterone synthesis in foetal
testes, changes in AGD, retained nipples, non-descending testes, agen-
esis of the epididymus and malformations of the external genitalia.
Among toxicologists (but not endocrinologists) there have been debates
Table 4
Revised Points-of-Departure (POD) and Reference Doses (RfD AA) for phthalates.
POD (mg/kg/d) UF POD adjusted (mg/kg/d) RfD AA (μg/kg/d)a
DBP 2 (LOAEL) 3 LOAEL - NOAEL 0.67 6.7
Endpoint Spermatocyte development
Species Rat
Reference Lee et al. (2004)
DIBP 10 (BMDLb) 1 10 100
Endpoint T suppression
Species Rat
Reference Hannas et al. (2011)
BBP 1 (BMDL) 1 1 10
Endpoint T suppression
Species Rat
Reference Furr et al. (2014)
DEHP 3 (LOAEL) 3 LOAEL - NOAEL 1 10
Endpoint Dysgenesis of genitalia
Species Rat
Reference Christiansen et al. (2010)
DINP 5.9 (BMDL) 1 5.9 59
Endpoint T suppression
Species Rat
Reference Clewell et al. (2013)
References.
Lee et al. (2004) Toxicology 2003: 221.
Hannas et al. (2011) Toxicological Sciences 123:206.
Furr et al. (2014) Toxicological Sciences 140:403.
Christiansen et al. (2010) Reproductive Toxicology 30:313.
Clewell et al. (2013) Reproductive Toxicology 35:56.
a RfD AA were derived by application of an UF = 100 to POD adjusted.
b Benchmark doses (lower limits, BMDL) were calculated by using the PROAST software, version 66.39, with a benchmark response of 5%. Details of the analyses
are shown in Supplementary Material.
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about the adversity of these effects, taking each of these in isolation. For
example, changes in AGD are considered as markers of androgen in-
sufficiency, but regarded by some as not adverse in themselves.
However, OECD guidance classes AGD changes as adverse and re-
commends their use for estimating NOAELs (OECD, 2008). Similarly,
the relevance of retained nipples in male rat offspring for human risk
evaluations is sometimes dismissed with the argument that this effect
does not occur in humans, but OECD guidance (OECD, 2013) stipulates
that retained nipples should be evaluated similarly to AGD changes. In
view of the underlying modes of action it is imperative to consider the
effect spectrum as a whole and to regard any of its manifestations as
adverse.
3.3. Dibutyl phthalate (DBP)
Our literature searches revealed that the RfDs for DIBP, BBP, DEHP
and DINP require updates, while the value of 10 μg/kg/d or 6.7 μg/kg/
d for DBP proposed by EFSA (EFSA, 2005a) and the Danish EPA (2009),
respectively can be taken without changes. Both are based on the study
by Lee et al. (2004) which estimated a LOAEL of 1–3 mg/kg/d for re-
duced spermatocyte development in the rat. Our searches did not
identify a study that documented effects at lower doses. The only dif-
ference between the EFSA and Danish EPA TDIs concerns the choice of
the UF (EFSA: 200; Danish EPA: 300). While EFSA did not itemise the
subfactors that made up their UF of 200, it presumably is composed of a
LOAEL to NOAEL extrapolation UF of 2 and a UF of 100 for species-
human extrapolation. In line with current ECHA and ECETOC guidance
(ECHA, 2012; ECETOC, 2010) which regards UFs between 3 and 10 as
appropriate, the Danish EPA (2009) employed 3 for LOAEL to NOAEL
conversion (assuming a LOAEL of 2 mg/kg/d). The NOAELs for tes-
tosterone synthesis suppression listed by Dorman et al. (2018) range
between 20 and 112 mg/kg/d, higher than the LOAEL reported by Lee
et al. (2004). The NOAELs for AGD changes and hypospadias are be-
tween 50 and 500 mg/kg/d. Thus, the Lee study is still the critical one,
and accordingly, we follow the Danish EPA and propose a POD of
0.67 mg/kg/d for use in calculating a PODI. Combined with the stan-
dard UF of 100, this translates into a RfD AA of 6.7 μg/kg/d (Table 4).
We attempted to derive a lower bound benchmark dose (BMDL) from
the Lee et al. data, but this resulted in an estimate of 0, due to the large
variability in the data for reduced spermatocyte development (all
benchmark dose estimations can be found in Supplementary Material).
3.4. Diisobutyl phthalate (DIBP)
We based our re-evaluation of RfDs for DIBP on the systematic re-
view by Yost et al. (2019) which highlighted the studies by Saillenfait
et al. (2008), Howdeshell et al. (2008a,b) and Hannas et al. (2011) as
highly reliable. These three studies reported some of the lowest PODs.
Saillenfait and colleagues established a NOAEL of 125 mg/kg/d for
shortened AGD and retained nipples. In this study they did not evaluate
suppressions of testosterone synthesis, as this can only be done by sa-
crificing foetuses which precludes subsequent measurements of AGD
and retained nipples. With testosterone suppression as the endpoint,
Hannas et al. and Howdeshell et al. estimated a quite similar, but
slightly lower, NOAEL of 100 mg/kg/d. Using the data by Hannas et al.,
we calculated a BMD of 50 mg/kg/d, with a BMDL of 10.9 mg/kg/d and
propose this value as a POD for phthalate MRA using the PODI. By
application of a UF = 100 for animal – human extrapolation, this
converts to a RfD AA of 100 μg/kg/d (Table 4).
3.5. Benzyl butyl phthalate (BBP)
For BBP, both EFSA (EFSA, 2005c) and the Danish EPA (2009) chose
the study by Tyl et al. (2004) as the basis for their TDIs. Tyl et al. es-
timated a NOAEL of 50 mg/kg/d based on shortened AGDs. However,
in relation to suppression of testosterone synthesis, the more recent
study by Furr et al. (2014) estimated 33 mg/kg/d as the NOAEL. In the
interest of achieving consistency in terms of endpoints, we selected
testosterone suppression as the basis for deriving an RfD AA. From the
Furr et al. data we estimated a BMD of 4 mg/kg/d with a BMDL of
1 mg/kg/d and suggest this value as a POD for use in phthalate MRAs.
With a UF = 100 this converts to 10 μg/kg/d as a RfD AA (Table 4).
3.6. Di(ethylhexyl) phthalate (DEHP)
In deriving their TDIs for DEHP, EFSA (EFSA, 2005b) and the
Danish EPA (2009) relied on a technical report by Wolfe and Layton
(2003) which estimated a NOAEL of 5 mg/kg/d for reduced testis
weight and effects on gametes in the rat. Many of the other endpoints
that make up the phthalate syndrome are responsive at higher doses:
Furr et al. (2014) saw significant reductions of testosterone synthesis at
100 mg/kg/d, the lowest dose for this endpoint among the studies
collated by Dorman et al. (2018). Selection of testosterone suppression
as the endpoint would make the DEHP POD comparable with DIBP and
BBP, but as this dose is considerably higher than the NOAEL from Wolfe
and Layton (2003) there are concerns about achieving sufficient pro-
tection. Effect doses related to AGD changes suffer from similar dis-
advantages: Dorman et al. identified the lowest reported NOAEL for
AGD changes as 10 mg/kg/d based on the study by Christiansen et al.
(2010). In agreement with Christensen et al. (2014) we identify
Christiansen et al. as the critical study that detected effects below 5 mg/
kg/d. These authors estimated a NOAEL of 3 mg/kg/d for retained
nipples. At this dose, however, mild dysgenesis of genitalia became
apparent which designates this dose as a LOAEL. Christensen et al.
employed a LOAEL to NOAEL extrapolation factor of 10 which, together
with the standard UF = 100 produced a RfD of 3 μg/kg/d. However, in
line with ECHA and ECETOC guidance (ECHA, 2012; ECETOC, 2010),
we propose a UF = 3 for a LOAEL to NOAEL conversion to yield a POD
of 1 mg/kg/d. With the standard UF = 100 this gives a RfD AA of
10 μg/kg/d (Table 4). We attempted to derive a BMDL from the
Christiansen et al. data, but due to the relatively large variability in the
responses, this produced a BMDL of 0. There was evidence of a clear
statistical dose-related trend in the formation of dysgenesis of genitalia:
the Akaike Information Criterion (AIC) of the best fitting model was
lower by more than 2 units than the AIC of the null model (Supple-
mentary Information).
3.7. Diisononyl phthalate (DINP)
The TDI proposed by the Danish EPA (2009) for DINP is 1600 μg/
kg/d, based on a NOAEL of 276 mg/kg/d for reduced testes weights in
mice. Since 2010, important studies appeared which documented ef-
fects at lower doses (Boberg et al. 2011). Critical is the study by Clewell
et al. (2013) who estimated a NOAEL of 50 mg/kg/d for testosterone
synthesis suppression and multi-nucleated gonocytes. Based on the
Clewell et al. data we estimated a BMD of 80 mg/kg/d with a BMDL of
5.9 mg/kg/d which we propose as a POD. This value translates into
59 μg/kg/d as the RfD AA by application of UF = 100 (Table 4). Effect
doses based on other phthalate syndrome endpoints are higher than
50 mg/kg/d and therefore unsuitable as a basis for deriving a RfD AA
(Dorman et al., 2018).
The remaining phthalates highlighted in the structure-activity ana-
lysis by Li et al. (2019) as active (e.g. DPP, DNHP, DHP, DIHP and
DCHP) and therefore relevant for inclusion in MRA are not considered
further here. These phthalates are commercially less relevant, are rarely
measured in biomonitoring studies, and data suitable for derivations of
POD and RfD are scarce. However, there are indications that at least
some of these phthalates (such as DNHP) are more potent than DBP and
DEHP in producing the phthalate syndrome (Furr et al., 2014).
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3.8. Application of revised RfD AA to phthalate MRA
Our analysis revealed that apart from DBP all other phthalates
considered here (DIBP, BBP, DEHP and DINP) required revisions of
their RfD AA. Our new proposed RfD AA differ in some respects from
previously used values. They are generally lower than the RfD AA de-
veloped by Kortenkamp and Faust (2010) and more similar to the TDI
based on EFSA and the Danish EPA. However, the impact of the new
RfD on the outcome of MRAs compared with previously derived HI
estimates is not immediately obvious. We therefore chose some of the
phthalate MRAs reported earlier as case studies to compare the HI
calculated using the new RfD AA with the outcomes using EFSA TDIs
and the Kortenkamp and Faust values (Table 5). Our selection and the
associated comparisons of HI is arbitrary and is not intended to be
Table 5
The application of revised RfD AA to selected previous mixture risk assessments. Based on the 95th percentiles of estimated Daily Intakes (DI 95P).
Hartmann et al., 2015
Adults DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 1.1 10 0.11 100 0.011 6.7 0.16
DIBP 3.4 10 0.34 200 0.017 100 0.034
BBP 0.23 500 0.00046 330 0.00069 10 0.023
DEHP 2.2 50 0.044 30 0.073 10 0.22
DINP 1500 0 1500 0 59 0
HI 0.49 0.10 0.44
MCR 2.0
Kranich et al., 2014
Adults DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 4.2 10 0.42 100 0.042 6.7 0.63
DIBP 7.8 10 0.78 200 0.039 100 0.078
BBP 8.8 500 0.018 330 0.027 10 0.88
DEHP 8 50 0.16 30 0.27 10 0.8
DINP 22 1500 0.014 1500 0.015 59 0.37
HI 1.39 0.39 2.76
MCR 3.1
Bekö et al. (2013)
Adults DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 10 10 1 100 0.1 6.7 1.49
DIBP 200 0.05 100 0.1
BBP 2.9 500 0.0058 330 0.0088 10 0.29
DEHP 16.9 50 0.34 30 0.56 10 1.69
DINP 1500 0 1500 0 59 0
HI 1.34 0.72 3.57
MCR 2.1
Dewalque et al., 2014
Adults DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 4.53 10 0.45 100 0.045 6.7 0.67
DIBP 6.29 10 0.63 200 0.031 100 0.063
BBP 1.12 500 0.0022 330 0.0034 10 0.112
DEHP 6.77 50 0.13 30 0.23 10 0.68
DINP 1500 0 1500 0 59 0
HI 1.22 0.31 1.53
MCR 2.3
Dong et al., 2018
Women DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 1.7 10 0.17 100 0.017 6.7 0.25
DIBP 1.6 10 0.16 200 0.008 100 0.016
BBP 0.87 500 0.0017 330 0.0026 10 0.087
DEHP 6.44 50 0.13 30 0.21 10 0.64
DINP 1500 0 1500 0 59 0
HI 0.46 0.24 1.00
MCR 1.6
Christensen et al., 2014
all ages DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 2.1 10 0.21 100 0.021 6.7 0.31
DIBP 0.8 10 0.08 200 0.004 100 0.008
BBP 1 500 0.002 330 0.003 10 0.1
(continued on next page)
A. Kortenkamp and H.M. Koch International Journal of Hygiene and Environmental Health 224 (2020) 113428
9
conclusive.
Relative to the EFSA TDI, the new proposed RfD AA generally
yielded higher HI estimates, even though the revised value for DIBP
increased from 10 μg/kg/d to 100 μg/kg/d. The exception is Hartmann
et al. (2015) where the HI decreased slightly from 0.49 to 0.44. Com-
pared to the HI based on the RfD AA by Kortenkamp and Faust the new
HI values are considerably higher.
In almost all MRAs that substituted the missing DIBP TDI with that
for DBP from EFSA, DIBP was a main contributor to the HI. With the
revised RfD AA, this is no longer the case.
Due to its low nominal value among the Kortenkamp and Faust RfD
AA, DEHP was often the sole major contributor to the HI. With the
revised RfD AA, DEHP and DBP now drive the HI, with the share of BBP
and DINP to the HI correspondingly increased.
3.9. The PODI as an alternative to the HI – does it remove distortions?
To evaluate concerns about the possible distorting effects on the HI
due to the use of differing UFs, we built RQs based on PODs, calculated
the corresponding PODI and compared the resulting values with those
obtained by using the HI (Table 6). As with the procedure used for
deriving the revised RfD AA, we applied UFs to the EFSA values to
produce corrected PODs better aligned with potency differences.
Among the EFSA TDI, this concerned the LOAEL of 2 mg/kg/d for DBP
which was converted to 1 mg/kg/d by using the factor of 2. Because the
UFs applied for extrapolating from POD to TDI were consistently 100,
this produced a PODI 100-times lower than the corresponding HI.
In contrast, the PODIs generated by using the Kortenkamp and Faust
PODs were not equivalent to the HI, mainly due to the difference be-
tween the UFs of 200 used for DBP, DIBP and BBP and that for DEHP.
The UF for DINP was the largest used, but due to the small value of the
corresponding RQ, the impact on the PODI was small. In general,
however, the distortive impact of the differing UFs was small.
As with the EFSA PODI, the PODIs obtained by using our revised
POD were equivalent to the HI, because uniform UF were used for the
conversion from POD to RfD AA used in connection with the HI method.
4. Discussion
In deriving revised phthalate RfD AAs appropriate for MRAs
(Table 4), we struck a balance between the need for consistency in
terms of common endpoints and the requirement of realising a rea-
sonable degree of protection. We achieved this by relying as much as
possible on data related to suppression of foetal testicular testosterone
synthesis, an effect common to many phthalates. Our own literature
searches and the outcomes of recent systematic reviews (Dorman et al.,
2018; Yost et al., 2019) showed that for DIBP, BBP and DINP testos-
terone suppression is the critical toxicity (in relation to the phthalate
syndrome). Other effects that make up the phthalate syndrome oc-
curred at higher doses. However, in the case of DBP and DEHP, reliance
on testosterone suppression would have been insufficiently protective,
as there is evidence that reduced spermatocyte development (DBP) and
Table 5 (continued)
DEHP 34.5 50 0.69 30 1.15 10 3.45
DINP 11.5 1500 0.0077 1500 0.0077 59 0.19
HI 0.99 1.19 4.07
RQ: Risk Quotient.
HI: Hazard Index.
MCR: Maximal Cumulative Ratio.
Bekö et al. (2013) PLoS ONE, 8(4). https://doi.org/10.1371/journal.pone.0062442.
Christensen et al. (2014), Regulatory Toxicology and Pharmacology. 69(3), pp. 380–389. https://doi.org/10.1016/j.yrtph.2014.04.019.
Dewalque et al. (2014), Toxicology Letters, 231(2), pp. 161–168. https://doi.org/10.1016/j.toxlet.2014.06.028.
Dong et al. (2018), Science of the Total Environment, 637–638, pp. 871–880. https://doi.org/10.1016/j.scitotenv.2018.05.064.
Hartmann et al. (2015), International Journal of Hygiene and Environmental Health, 218(5), pp. 489–499. https://doi.org/10.1016/j.ijheh.2015.04.002.
Kranich et al. (2014), Environmental Science and Technology, 48(1), pp. 706–712. https://doi.org/10.1021/es402569k.
Table 6
The Hazard Index (HI) and Point-of-Departure-Index (PODI) in mixture risk assessment – comparison of outcomes. Based on the 95th percentiles of estimated Daily
Intakes (DI 95P) in Kranich et al. (2014).
DI 95P (μg/kg/d) EFSA TDI (μg/kg/d) RQ (EFSA) RfD AA Kortenkamp (μg/kg/d) RQ (Kortenkamp) New RfD AA (μg/kg/d) RQ (new)
DBP 4.2 10 0.42 100 0.042 6.7 0.63
DIBP 7.8 10 0.78 200 0.039 100 0.078
BBP 8.8 500 0.018 330 0.027 10 0.88
DEHP 8 50 0.16 30 0.27 10 0.8
DINP 22 1500 0.015 1500 0.015 59 0.37
HI 1.39 0.39 2.76
DI 95P (μg/kg/d) EFSA POD (μg/kg/d) RQ POD Kort (μg/kg/d) RQ New POD (μg/kg/d) RQ
DBP 4.2 1000 0.0042 20000 0.00021 670 0.0063
DIBP 7.8 1000 0.0078 40000 0.000195 10000 0.00078
BBP 8.8 50000 0.000176 66000 0.000133 1000 0.0088
DEHP 8 5000 0.0016 3000 0.002667 1000 0.008
DINP 22 150000 0.000147 750000 2.93E-05 5900 0.003729
PODI 0.0139 0.0032 0.0276




MoE: Margin of Exposure.
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mild dysgenesis of genitalia (DEHP), all components of the phthalate
syndrome, occur at lower doses.
In the case of DBP and DEHP it was not possible to completely avoid
the imbalances that arise from the inaccurately defined effect magni-
tudes associated with using NOAELs or LOAELs as toxicological metrics.
This would have required high quality dose-response analyses for all
the endpoints in question, but the data to support such efforts are not
available. Until better data become accessible, this flaw and the un-
certainties this introduces to phthalate MRA have to be accepted.
With DIBP, BBP and DINP we achieved the required consistency by
estimating BMDLs for suppression of testosterone synthesis. We based
these estimates on a benchmark response (BMR) of 5% as recommended
as the default in EFSA guidance (EFSA et al., 2017). This re-
commendation is in line with analyses of 246 developmental and re-
productive toxicity studies (Allen et al. 1994) and of experiments from
the US National Toxicology Programme (Bokkers and Slob, 2007)
which established that the BMDL for a BMR of 5% was on average close
to the respective NOAELs. Our BMDLs were 10-fold (DIBP, DINP) or 30-
fold (BBP) lower than the corresponding NOAELs which fell in the
window defined by the BMDL and BMDU. Fournier et al. (2016) have
presented a BMD for BBP based on 50% testosterone suppression. We
did not follow this approach, for two reasons: First, it would have
violated the principle of utilising reference doses derived for similar
effect magnitudes in mixture risk assessments. Secondly, it is at present
unclear whether any reduction in fetal testosterone levels, however
small, triggers adverse effects, or whether such effects materialise only
when testosterone suppressions falls below a certain critical value. To
our knowledge, there are no data that support 50% testosterone sup-
pression as being that critical value. Furthermore, the BMD philosophy
is to safeguard against the occurrence of any adversity, and this is
achieved with a BMR of 5%.
There is a relatively high degree of uncertainty in our BMDL esti-
mates for testosterone synthesis suppression based on the three key
studies we utilised (Clewell et al. 2013; Furr et al. 2014; Hannas et al.
2011). This is reflected by BMD: BMDL ratios of 5, 4 and 13 for DIBP,
BBP and DINP, respectively (Supplementary Material). In principle, this
uncertainty may be due to model uncertainty, data variance, or both
(Haber et al. 2018). However, since we used model averaging in de-
riving our BMDL, the influence of any particular dose response model
on the BMD: BMDL ratio is lessened considerably. We therefore believe
that data variance is the main reason for the uncertainty of our esti-
mates. This uncertainty could have been reduced somewhat had we
been able to account for litter effects. However, this was not possible
because the data in Clewell et al. (2013), Furr et al. (2014), and Hannas
et al. (2011) were reported as overall means.
All in all, our proposed revised RfD AA are lower than the values
derived by EFSA (2005 a, b, c, d) and those from the Danish EPA (2009)
(Table 3). The RfD AA in Kortenkamp and Faust (2010) could not take
account of new evidence of low dose phthalate effects that appeared
after 2010 and are therefore insufficiently protective. They should not
be used in future phthalate MRAs.
For some known reprotoxic phthalates we did not derive RfD AAs
because these phthalates have only recently been detected in exposure
assessments (Bertoncello et al., 2018). In addition, the available toxicity
data is limited or rather old. However, phthalates with alkyl chain
lengths of C5–C7, between DBP and DEHP, are considered more potent
than DBP or DEHP themselves. Preliminary RfD AAs for such phthalates
should therefore be lower than 6.7 μg/kg/d or 10 μg/kg/d, respectively,
in the range between 1 and 5 μg/kg/d. These preliminary values could
be used for the assessment of exposure scenarios that included these
phthalates.
4.1. HI or PODI?
Our comparisons of the outcome of the familiar HI-based MRAs with
those produced by using the PODI did not reveal striking differences.
This is due to the separation of UFs for adjusting data quality (LOAEL –
NOAEL extrapolations) from those for realising protection goals. After
adjustment for data quality, a UF = 100 was consistently applied to the
resulting POD which produces results equivalent to the HI, with no
distortions. Thus, provided there is a clear separation of these two
classes of UFs, either HI or PODI can be used, as both methods produce
equivalent assessment outcomes. With the HI, a value larger than 1
signals that the combined exposures to the selected phthalates exceeds
exposures judged to be acceptable. The PODI is the inverse of the MoE
between human exposures and doses associated with borderline effects
in experimental animals. A PODI of 0.01 or smaller indicates MoEs of
100 or larger. If a clear separation of the two types of UF cannot be
made, we follow the arguments advanced by Wilkinson et al. (2000) in
favour of the PODI.
4.2. A call for retiring the fixation on HI = 1
As already pointed out, most previous phthalate MRAs have con-
sidered an HI below 1 as signalling acceptable combined exposures.
This tacitly assumes that the “risk cup” for male developmental dis-
orders related to disruption of androgen action is solely composed of
phthalates. However, this stance disregards all the evidence from the
experimental literature of combined effects between phthalates and a
wide variety of other substances also capable of interfering with hor-
mone action (Howdeshell et al. 2017; Kortenkamp, 2019). These stu-
dies show that the developing male reproductive system can be dis-
rupted from multiple different points of entry. These include not only
suppression of InsL3 and testosterone synthesis as with phthalates, but
also androgen receptor antagonism (certain dicarboximide pesticides,
parabens, bisphenol A), direct inhibition of steroidogenic and steroid-
converting enzymes (certain imidazole and phenylurea pesticides, and
the drug finasteride), interference with the transport of androgen pre-
cursors (lipid-lowering drugs), disruption of prostaglandin signalling by
inhibition of Cox enzymes (certain analgesics and a wide variety of
phenolic substances) and poorly defined pathways triggered by poly-
chlorinated dioxins and biphenyls. Thus, common adverse outcomes
overlapping with the phthalate syndrome can be induced through
multiple interacting and converging pathways that involve numerous
chemicals with diverse structural features. Human exposure to many of
these substances is as widespread and common as to phthalates.
This evidence calls for retiring the fixation on HI = 1 as the
benchmark for evaluating the outcome of phthalate MRAs. HI = 1
leaves no room for co-exposures to other substances that also disrupt
the normal development of the male reproductive system.
We suggest two, not mutually exclusive, options for addressing this
challenge:
First, future MRAs should be expanded to consider not only
phthalates, but also other substances capable of inducing male devel-
opmental toxicity through hormonal mechanisms. If the selection of
relevant chemicals is comprehensive, then HI = 1 (equivalent to
PODI = 0.01) can remain unchanged as the evaluation criterion.
However, this option will be difficult to implement immediately. There
are considerable challenges in collating the required exposure in-
formation for all substance of concern. Similar problems are to be ex-
pected when it comes to compiling toxicity data of suitable quality.
Alternatively, phthalates can be grouped together as before and
subjected to MRA but evaluated against a lowered HI or PODI. The
advantage of this approach is in its pragmatism: As pursuit of the first
option is likely to be a complicated and time-consuming effort, phtha-
late MRAs can continue until more comprehensive assessments are
available. However, this begs the question as to the degree to which the
HI (or PODI) should be lowered.
4.3. What is an acceptable HI or PODI for phthalate MRAs?
The answer to this question will depend on the contribution of
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phthalates to the HI (or PODI) relative to the entire “risk cup” of male
developmental toxicants beyond phthalates. This requires that the
number of chemicals contributing to an “anti-androgen” exposure sce-
nario is known, together with the relative impact of each corresponding
RQ to the HI or PODI. For other anti-androgens acting together with
phthalates these figures are currently unknown. Thus, the choice of an
acceptable HI below 1 is at present arbitrary.
Nevertheless, informed guesses can be made. Considering that in
addition to the group of phthalates as a whole at least 10 further sub-
stances are likely to contribute to the combined exposures
(Kortenkamp, 2019), it is not unrealistic to assume that phthalates
alone make up 10% of the risk cup. To accommodate the impact of
these other substances, phthalates would have to be evaluated using a
HI of 0.1. However, this assumes that the contribution of anti-andro-
genic non-phthalates is evenly distributed. If however some of these
chemicals make a disproportionately large contribution to the HI, while
others add little, the phthalate share of the risk cup could increase to
perhaps 20%. Accordingly, the HI of phthalates alone would have to be
evaluated against a HI of 0.2.
We emphasise that these considerations are speculative, but not
implausible. We therefore recommend 0.1–0.2 as a point of orientation
to guide the interpretation of phthalate MRAs until more information
about exposures to other anti-androgens becomes available to allow
upwards revisions of these values.
4.4. A framework and workflow for MRAs beyond phthalates
To realise MRAs beyond phthalates that also include other chemi-
cals capable of producing male developmental toxicity via hormonal
modes of action it is first necessary to gain a sense of which chemicals to
include. Based on reviews of experimental mixture studies (Howdeshell
et al. 2017; Kortenkamp, 2019) we suggest that a minimum set of
chemicals to be assessed together with phthalates should comprise
pesticides such as vinclozolin, prochloraz, procymidone, linuron, pain
killers including paracetamol, aspirin and ibuprofen, pharmaceuticals
such as finasteride, ketoconazole, and the lipid-lowering drug sim-
vastin, poly-chlorinated dibenzo-dioxins and other dioxin-like pollu-
tants, poly-brominated diphenyl ethers, perfluoro octanoic acid, per-
fluoro octanoic sulfonate and phenolics such as bisphenol A and
butylparaben.
It is suggested to begin an MRA with a scoping analysis by appli-
cation of the HI. The aim of this step would be to assess whether the
sum of RQ exceeds HI = 1. At this stage of the analysis, TDI, ADI or RfD
for the critical toxicity of each of the chemicals, regardless of the
availability of RfD for male developmental toxicity may be used. A
second step will be to establish whether simultaneous exposure to all
the chemicals in the “risk cup” is likely, and, if appropriate, to focus
only on those relevant to simultaneous exposures.
If this analysis reveals unacceptable combined exposures (HI = 1),
the assessment should be refined by focusing strictly on effect doses and
RfD related to male developmental toxicity by hormonal mechanisms.
To avoid possible distortions by using differing UFs in the HI method,
application of the PODI suggests itself.
5. Conclusions
A set of phthalate RfDs for use in MRA is required that incorporates
new information about low dose effects and is commensurate with the
scientific principles of mixture effect assessments under dose addition.
We have proposed new RfDs that match these requirements. We con-
clude that the fixation on HI = 1 that has dominated previous phthalate
MRAs should be retired. The idea that HI = 1 for the assessment group
of phthalates signals minimal risks and no need for regulatory action is
misguided. It ignores that there is co-exposure to other anti-androgenic
chemicals that also contribute to risks. Until more comprehensive as-
sessments of phthalates together with other anti-androgens become
available, we propose the use of a HI of 0.1–0.2 (PODI = 0.001–0.002)
as a provisional pragmatic solution.
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